<div id="readability-page-1"><p>Blair William &amp; Co. IL bought a new position in shares of  Solid Biosciences Inc. (NASDAQ:SLDB - Free Report) during the second quarter, according to the company in its most recent 13F filing with the Securities &amp; Exchange Commission. The firm bought 165,700 shares of the company's stock, valued at approximately $807,000. Blair William &amp; Co. IL owned about 0.21% of Solid Biosciences at the end of the most recent quarter.</p><div><p><span></span><span>Get <strong>Solid Biosciences</strong> alerts:</span></p></div><ul><li>Brutal 2025 for Sarepta—Analysts Still Call for 179% Upside</li></ul><p>A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in SLDB. Adage Capital Partners GP L.L.C. boosted its holdings in  Solid Biosciences by 285.0% during the first quarter. Adage Capital Partners GP L.L.C. now owns 6,729,484 shares of the company's stock worth $24,899,000 after buying an additional 4,981,400 shares during the last quarter.  Bain Capital Life Sciences Investors LLC boosted its holdings in  Solid Biosciences by 96.1% during the first quarter. Bain Capital Life Sciences Investors LLC now owns 7,911,669 shares of the company's stock worth $29,273,000 after buying an additional 3,877,087 shares during the last quarter.  Siren L.L.C. boosted its holdings in  Solid Biosciences by 97.8% during the first quarter. Siren L.L.C. now owns 7,415,905 shares of the company's stock worth $27,439,000 after buying an additional 3,666,864 shares during the last quarter.  MPM Bioimpact LLC bought a new position in  Solid Biosciences during the first quarter worth about $6,077,000.  Finally, Redmile Group LLC boosted its holdings in  Solid Biosciences by 228.2% during the first quarter. Redmile Group LLC now owns 2,019,171 shares of the company's stock worth $7,471,000 after buying an additional 1,403,925 shares during the last quarter. Institutional investors own  81.46% of the company's stock. </p><h2>Wall Street Analysts Forecast Growth</h2><p>Several equities analysts have recently weighed in on the company. Wedbush cut their price objective on Solid Biosciences from $17.00 to $14.00 and set an &#34;outperform&#34; rating on the stock in a report on Wednesday, August 13th. Weiss Ratings  reiterated a &#34;sell (d-)&#34; rating on shares of Solid Biosciences in a report on Wednesday, October 8th. Wall Street Zen upgraded Solid Biosciences from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a report on Saturday, October 11th. Chardan Capital  reissued a &#34;buy&#34; rating and issued a $15.00 target price on shares of Solid Biosciences in a research report on Thursday, August 14th. Finally, Citigroup began coverage on Solid Biosciences in a research report on Thursday, June 26th. They issued a &#34;buy&#34; rating and a $14.00 target price on the stock. One investment analyst  has rated the stock with a Strong Buy rating, ten have issued  a Buy rating and one  has given a Sell rating to the stock. According to MarketBeat, the stock  has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $15.00.</p><ul><li>Sarepta Drops 42% on Fatalities; Markets Eye Solid Biosciences</li></ul><p><b>Get Our Latest Stock Report on SLDB</b></p><h2>Solid Biosciences Stock Down 2.5%</h2><p>NASDAQ:SLDB opened at $6.16 on Friday. The firm has a market capitalization of $479.68 million, a price-to-earnings ratio of -2.20 and a beta of 2.53. Solid Biosciences Inc. has a twelve month low of $2.41 and a twelve month high of $7.37. The stock's 50 day moving average price is $5.76 and its two-hundred day moving average price is $4.77. </p><ul><li>Can Solid Biosciences Challenge Sarepta in the DMD Market?</li></ul><p>Solid Biosciences (NASDAQ:SLDB - Get Free Report) last posted its earnings results on Tuesday, August 12th. The company reported ($0.42) earnings per share for the quarter, topping analysts' consensus estimates of ($0.51) by $0.09.  As a group, analysts anticipate that  Solid Biosciences Inc. will post -2.84 earnings per share for the current year. </p><h2>Solid Biosciences Company Profile</h2> (Free Report)<p>Solid Biosciences Inc, a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia.</p><h2>Further Reading</h2><ul><li>Five stocks we like better than Solid Biosciences</li><li>How to Use the MarketBeat Stock Screener </li><li>Salesforce’s Long-Awaited Inflection is Here: Rally On!</li><li>What is the MACD Indicator and How to Use it in Your Trading</li><li>Rocket Lab USA Receives Wall Street Validation: Time to Buy?</li><li>Why Are These Companies Considered Blue Chips?</li><li>Archer Buys Rival's Patent Treasure Trove in Strategic Move</li></ul><p><strong>Want to see what other hedge funds are holding SLDB?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Solid Biosciences Inc. (NASDAQ:SLDB - Free Report).</p><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U0xEQg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U0xEQg"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Solid Biosciences Right Now?</h2><p>Before you consider Solid Biosciences, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Solid Biosciences wasn't on the list.</p><p>While Solid Biosciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

SLDB

<p>Blair William & Co. IL acquired 165,700 shares of Solid Biosciences Inc. (NASDAQ:SLDB) valued at approximately $807,000 during Q2, according to a recent SEC filing. This purchase brings their ownership to about 0.21%. Other institutional investors have also increased their stakes in SLDB, with significant boosts from Adage Capital Partners and Bain Capital Life Sciences. Analysts have mixed ratings on the stock, with a consensus target price of $15.00. Solid Biosciences reported earnings of ($0.42) per share, exceeding estimates.</p>

165,700 Shares in Solid Biosciences Inc. $SLDB Purchased by Blair William & Co. IL